Hope in Hard Places: A Potential New Option for Patients with Pancreatic Cancer
Update: 2025-07-24
Description
Metastatic pancreatic cancer remains one of the deadliest cancers, but a new approach is taking shape - and it's showing promise in early clinical studies.
In this episode, Dan Schmitt, President and CEO of Actuate Therapeutics, shares how elraglusib, an investigational targeted therapy, may provide a new option for patients with metastatic pancreatic cancer. We explore the urgent unmet need and why Dan thinks this could be a turning point for one of oncology's toughest challenges.
In this episode, Dan Schmitt, President and CEO of Actuate Therapeutics, shares how elraglusib, an investigational targeted therapy, may provide a new option for patients with metastatic pancreatic cancer. We explore the urgent unmet need and why Dan thinks this could be a turning point for one of oncology's toughest challenges.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
